A Study of the Effect of Myectomy on the Sudden Cardiac Death Risk in Hypertrophic Cardiomyopathy


About this study

The primary purpose/objective of this study is to determine whether myectomy as a management option for severe hypertrophic cardiomyopathy (HCM) reduces the incidence of sudden cardiac death.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • We will include patients by reviewing the HCM and myectomy clinical databases at Mayo from 2005-2016.

Exclusion Criteria: 

  • Patients in the database that have no research authorization or those with HCM phenocopies (such as Fabry’s disease, etc.) will be excluded.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Christopher McLeod, M.B., Ch.B., Ph.D.

Contact us for the latest status

Contact information:

Jeffrey Geske M.D.



More information


Publications are currently not available